Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 25;236:108961. doi: 10.1016/j.clim.2022.108961

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Vaccine-induced SARS-CoV-2-specific IL-2 (A) and IFN-γ (B) and IL-2 and/or IFN-γ (C)-producing T cells and SARS-CoV-2 anti-spike IgG antibodies as determined using the Abbott assay (D), GenID assay (E), and both (F) at T1 and T2.

A) T1 (n = 50): Not reactive, 21 (42.0%); borderline, 6 (12.0%); reactive, 18 (36.0%); invalid, 5 (10.0%). T2 (n = 58): Not reactive, 21 (36.2%); borderline, 6 (10.3%); reactive, 15 (25.9%); invalid, 16 (27.6%). T1 vs. T2 (p = 0.73).

B) T1 (n = 50): Not reactive, 37 (74.0%); borderline, 0 (0.0%); reactive, 11 (22.0%); invalid, 2 (4.0%). T2 (n = 58): Not reactive, 34 (58.6%); borderline, 4 (6.9%); reactive, 14 (24.1%); invalid, 6 (10.3%). T1 vs. T2 (p = 0.12).

C) T1 and/or T2 (n = 60): Not reactive, 20 (33.3%); borderline, 6 (10.0%); reactive, 31 (51.7%); invalid, 3 (5.0%).

D) T1 (n = 50): Positive, 44 (88.0%)^a; negative, 6 (12.0%)^b. T2 (n = 58): Positive, 52 (89.7%)^a; negative, 6 (10.3%)^b. T1 vs. T2 (p = 1.0)^e.

E) T1 (n = 49): Positive, 44 (89.8%)^c; negative, 5 (10.2%)^d. T2 (n = 58): Positive, 53 (91.4%)^c; negative, 5 (8.6%)^d. T1 vs. T2 (p = NS)^e.

F) T1 and/or T2 (n = 60): Positive, 55 (91.7%); negative, 5 (8.3%).

The dashed horizontal lines indicate the cut-off for positivity (reactive); the area between the horizontal lines indicates the borderline zone used in each GenID assay.

^aPositive refers to antibody levels >16%.

^bNegative refers to antibody levels ≤16%.

^cPositive refers to antibody concentration > 50 AU/mL.

^dNegative refers to antibody concentration ≤ 50 AU/mL.

^eMcNemar's test for paired nominal data was used.

IFN-γ, interferon-γ; IL-2, interleukin-2; SARS-CoV-2, NS, not significant; severe acute respiratory syndrome-coronavirus type-2; T1, timepoint 1; T2, timepoint 2.